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Background: Accurate pre-operative imaging in pancreatic cancer helps avoid unsuccessful surgical
explorations and forewarns surgeons regarding aberrant anatomy. This review aimed to determine the role
of current imaging modalities in the diagnosis and determination of resectability of pancreatic and
peri-ampullary adenocarcinomas.
Methods: A systematic search of the scientific literature was carried out using EMBASE, PubMed/
MEDLINE and the Cochrane Central Register of Controlled Trials for the years 1990 to 2011 to obtain
access to all publications, especially randomized controlled trials, reporting on the diagnostic accuracy of
ultrasonography, multi-detector computed tomography (MDCT), magnetic resonance imaging (MRI),
endoscopic ultrasonography (EUS) or positron emission tomography (PET)-computed tomography (CT)
and the evaluation of resectability of pancreatic and peri-ampullary adenocarcinomas.
Results: Based on 66 articles analysed in the review, MDCT and MRI/MRCP have comparable sensitivity
and specificity rates for diagnosis and staging of pancreatic cancers. EUS offers the best sensitivity and
specificity rates for lesions <2 cm. Improved staging has been noted when PET-CT scans are added to
pre-operative evaluation.
Conclusions: MDCT with angiography or MRI/MRCP should constitute the first imaging modality in
suspected pancreatic adenocarcinomas. EUS is recommended for assessing lesions not clearly
detected, but suspected, on CT/MRI and in tumours considered ‘borderline resectable’ on MDCT to
assess vascular involvement. PET-CT in locally advanced lesions will help rule out distant metastases.
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Introduction
Carcinomas of the pancreas, although uncommon, are amongst
the leading causes of cancer-related deaths around the world.
According to the American Cancer Society, the relative 1-year
survival is only 24%, and the overall 5-year survival rate is 5%1
and with similar outcomes reported worldwide.2–4 Complete sur-
gical resection with chemotherapy (when indicated) offers the
best outcomes in this cancer.5 However, owing to the insidious
onset of the disease and the delayed presentation of patients,
surgery with a curative intent may not always be possible. Owing
to the morbidity associated with a surgical exploration that is
likely to be unsuccessful, pre-operative determination of the
extent of the disease assumes significance. As a result of the
increased morbidity and technical difficulty associated with aber-
rant arterial anatomy, an accurate pre-operative assessment of the
vascular anatomy is important.6 Over the years, various radiologi-
cal imaging modalities for the pancreas have been used for the
diagnosis and staging of these cancers including abdominal
ultrasonography, computed tomography (CT) scans, magnetic
resonance imaging (MRI), laparoscopy and endoscopic
ultrasonography (EUS). The aims of this review were to define the
role of pre-operative imaging in the evaluation of pancreatic
adenocarcinomas by providing the evidence available to date on
each of these modalities.
This paper was presented at the 2010 IHPBA meeting in Buenos Aires,
Argentina.
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Methods
A systematic search of the scientific literature was carried out
using EMBASE, PubMed/MEDLINE and the Cochrane Central
Register of Controlled Trials for the years 1990–2011 to obtain
access to all publications, especially randomized controlled trials,
that reported on the diagnostic accuracy of ultrasonography, CT,
MRI or EUS and evaluation of resectability of pancreatic and
peri-ampullary adenocarcinomas.
The search strategy was that described by Dickersin et al.7 with
the appropriate specific search terms, namely, ‘peri-ampullary
cancer’, ‘pancreatic cancer’, ‘diagnosis’, ‘staging’, ‘resectability’,
‘computed tomography’, ‘CT’, ‘magnetic resonance imaging’,
‘MRI’, ‘ultrasonography’, ‘endoscopic ultrasonography’, ‘EUS’, ‘lap-
aroscopy’, ‘positron emission tomography’, ‘PET’, ‘randomized
controlled trials’, ‘review’ and ‘meta-analysis’. All available major
publications from the past 21 years were retrieved.
Inclusion criteria:
1 Original articles on the role of CT scan/MRI or MRCP/
ultrasonography (abdominal and laparoscopic)/PET-CT/
EUS in the diagnosis, determination of the extent of
disease and resectability of pancreatic and peri-ampullary
adenocarcinoma.
2 Original articles comparing CT scans, MRI or MRCP, ultra-
sonography (abdominal and laparoscopic), PET-CT and/
or EUS in the diagnosis, determination of the extent of
disease and resectability of pancreatic and peri-ampullary
adenocarcinoma.
Exclusion criteria:
1 Case reports.
2 Articles on the imaging of tumours other than adenocarcicoma.
From the retrieved articles, only papers reporting on ultra-
sonography, CT, MRI/MRCP, EUS or laparoscopy in the diagno-
sis, staging and the determination of resectability in patients
with pancreatic and peri-ampullary cancer were included in the
review.
For clarification, the term staging has been used to indicate the
ability of the imaging modality to delineate the tumour, nodal and
metastatic disease whereas the term resectability is mainly used to
indicate technical resectability in the absence of distant metastases
and vascular involvement (beyond the definition of borderline
resectable disease – for definition see below).
Results
Using the above search strategy, 351 articles were identified of
which only 67 articles were analysed in this review (Fig. 1). These
included three articles on abdominal ultrasonography,8–10 23 on
CT and CT angiography,11–33 4 on MRI/MRCP,34–37 2 on laparo-
scopic staging and laparosopcic ultrasonography,38,39 9 on PET
and PET-CT,40–48 3 on EUS49–51 and 23 comparing the various
modalities.52–74
A recent review by Low et al.75 provides useful information
in differentiating benign from malignant lesions of the pancreas
and hence this aspect has not been addressed in the present
review. Other important reviews published on the topic in past
11 years include the role of a standard MR in pre-operative
imaging of pancreatic masses76 and the use of an MR protocol
including non-contrast T1-weighted fat-suppressed and dynamic
gadolinium-enhanced gradient-echo imaging in pancreatic
cancer by Vachiranubhap et al.77 Bipat et al.,78 in 2005, published
a sentinel meta-analysis on the role of ultrasonography, CT and
MRI for the diagnosis and determination of resectability of pan-
creatic adenocarcinoma in which they concluded that helical CT
was the preferred imaging modality.
Diagnosis and staging: imaging modalities
Abdominal ultrasonography in pancreatic cancer
Ultrasonography is amongst the most widely available and often
the first investigative imaging modality used to assess patients
Figure 1 Flow chart of the search strategy employed
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with hepatopancreatobiliary complaints or even non-specific
abdominal pain. Karlson et al.8 reported a diagnostic sensitivity of
up to 90% for exocrine pancreatic tumours. Moreover, the pres-
ence of obvious hepatic metastases on ultrasonography will often
prevent the need for further imaging.
However, in general, body habitus, the retroperitoneal location
of the pancreas obscured often by bowel gas, as well as the
operator-dependant nature of the investigation preclude the use
of ultrasonography as an accurate staging modality.
Morrin et al.,10 using gray scale and colour Doppler ultrasonog-
raphy of the abdomen, were able to demonstrate results similar to
helical CT and CT angiography in detecting venous involvement.
The role of the real-time imaging modality of contrast-enhanced
ultrasonography in pancreatic tumours has been trialled since the
late 1990s.9 Kitano et al.52 used coded phase inversion harmonic
ultrasonography to overcome the limitations from these previous
techniques and demonstrated a higher sensitivity of this tech-
nique compared with contrast-enhanced CT but similar to EUS
for detecting lesions 2 cm.
Computed tomography (CT)
CT scanners have developed tremendously over the past few
decades resulting in the improved resolution and hence their diag-
nostic capability. The thin-cut (64 section) intravenous contrast-
enhanced multi-detector CT (MDCT) is the radiological
investigation of choice.79 The scans are performed in phases, as
follows the non-contrast, arterial, pancreatic parenchymal and the
portal venous phases. MDCT allows rapid anatomic coverage
coupled with excellent spatial resolution.12
The sensitivity of CT in the detection of pancreatic cancers
has improved over the years with the advent of multi-phasic
scans and lies between 75–100% with a specificity of
70–100%.11,13,15,52,53,62,63,72 However, in spite of these improve-
ments, the sensitivity of CT scan for lesions 2 cm is between
68–77%13,52 with an accuracy of 77%.63 However, for tumours
>2 cm, the sensitivity may be as high as 98%.52
Pancreatic carcinomas on CT appear mainly hypoattenuating
especially on the arterial phase. However, they have also been
noted to be isoattenuating in 11% of individuals in which pan-
Figure 2 Algorithm outlining the role of the individual imaging modalities in the management of pancreatic and peri-ampullary cancers.
MDCT, multi-detector computed tomography; MRI, magnetic resonance imaging; MRCP, magnetic resonance cholangiopancreatography;
PET-CT, positron emission tomography-computed tomography; EUS, endoscopic ultrasonography; ERCP, endoscopic retrograde
cholangiopancreatography
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creatic or biliary duct dilation are signs that may indicate the
presence of an underlying pathology.28 The pancreatic tumours
noted to be hyperattenuating are mainly the neuroendocrine
tumours.24 The pancreatic parenchymal and the portal venous
phase appear to be similar but better than the arterial phase for
delineating pancreatic adenocarcinomas.17,26 However, for vascu-
lar invasion, the sensitivity of images obtained in the portal
venous phase are better than those obtained in the pancreatic or
arterial phases as images obtained in the pancreatic phase dem-
onstrated more flow artefacts and decreased attenuation in the
superior mesenteric vein, compared with the artefacts revealed on
images obtained in the portal venous (hepatic) phase.16
Imbriaco et al.18 found thin-section single-phase MDCT to be
very accurate for the diagnosis and assessment of resectability in
patients with a suspected pancreatic neoplasia owing to the
optimal tumour-to-pancreas contrast and maximal pancreatic
parenchymal and peri-pancreatic vascular enhancement. They
also found that it allowed visualization of the entire liver and the
whole upper abdomen during the portal phase for accurate iden-
tification of liver metastases and peritoneal seeding.
CT criteria for unresectable disease formerly included findings
such as extrapancreatic disease involving the liver or peritoneum,
and contiguous invasion of adjacent organs such as the stomach
and colon, as well as involvement of peri-pancreatic vessels.27 In
1997, Howard et al.56 reported a sensitivity and specificity of 63%
and 100%, and an overall accuracy of 86%. However, Lu et al.25
and Diehl et al.15 found the sensitivity rates to be 84% and 91%,
respectively. Karmazonovsky et al.,20 in 2005, found that spiral CT
had a sensitivity, specificity, negative predictive value (NPV), posi-
tive predictive value (PPV) and accuracy of 79%, 82%, 91%, 62%
and 81%, respectively, in predicting unresectability. They also
found that the sensitivity, specificity, positive predictive value,
negative predictive value and accuracy of spiral CT in the diagno-
sis of vascular invasion were 94%, 84.2%, 94%, 84%, and 91.3%,
based on their correlation with the intra-operative findings.
The increasing surgical aggression in terms of pancreatic resec-
tions that have gone hand in hand with the refinements in tech-
niques of surgery, coupled with advancements in chemotherapy
and radiotherapy have now led to the development of yet another
intermediate disease stage: borderline resectable disease.21,29,31 By
definition,30 borderline resectable tumours are those tumours that
exhibit the following: (i) encasement of a short segment of the
hepatic artery, without evidence of tumour extension to the celiac
axis, that is amenable to resection and reconstruction; and (ii)
tumour abutment of the superior mesenteric artery involving
<180° of the circumference of the artery or short-segment occlu-
sion of the superior mesenteric vein, portal vein or their conflu-
ence with a suitable option available for vascular reconstruction
because the veins are normal above and below the area of tumour
involvement. This stage strongly relies on the accurate delineation
of peripancreatic vascular involvement based on CT imaging.
Brugel et al.14 confirmed that thin-slice multiplanar reconstruc-
tions obtained with multislice helical CT provided an exact
depiction of the spatial relation between the tumour and the
potentially invaded vessels and thus had the capability to improve
the assessment of local resectability. Kaneko et al.19 retrospectively
compared multidetector computed tomographic angiography
(MDCTA) done pre-operatively to the actual surgical outcomes
with the aim of determining the value of MDCTA in predicting
resectability of pancreatic head cancers. In this previous study,
MDCTA was found to have a sensitivity, specificity, positive pre-
dictive value, negative predictive values and accuracy of 100%,
71%, 85%,100% and 89% which was similar to the results
reported by Fusari et al.53 and Zamboni et al.32 The additional
finding of the study by Zamboni et al.32 was the lack of evidence
suggesting varying results from the various generations of MDCT
scanners used.
Shrikhande et al.29 identified 12 patients with borderline resec-
table disease in a mixed pathological cohort of pancreatic adeno-
carcinomas, solid pseudopapillary and neuroendocrine tumours
according to the MD Anderson Cancer Centre classification.30
They correlated the MDCT images with the intra-operative find-
ings. Eight of the 12 patients actually underwent a curative R0
resection while another 2 had microscopically positive margins
(R1 resections). Based on this they determined that a grading
system based on three radiological features on MDCT, viz.
maximum degree of circumferential contact (CC), length of
contact of the tumour with major vessels (LC) and luminal nar-
rowing of vessels at the point of contact with the tumour (venous
deformity, VD) is helpful to predict which patients with appar-
ently borderline disease may actually be offered an up-front,
potentially curative surgical resection. This grading system needs
to be validated in a larger cohort of patients with pancreatic
adenocarcinoma.
Similarly, Kent et al.22 have proposed a CT grading system for
pancreaticobiliary tumours. This five-point scale describes the
radiographical relationship of the pancreatobiliary mass to adja-
cent vessels, viz. portal vein, superior mesenteric vein, superior
mesenteric artery and celiac trunk. An increasing grade has been
shown to be associated with a higher probability of unresectability
and microscopic positive resection margins.22
Zhao et al.33 performed a recent meta-analysis on the role of CT
in the diagnosis and determination of vascular invasion in pan-
creatic and periampullary cancer. Based on the results obtained
from the 18 studies selected, CT was found to have a sensitivity
and specificity of 85% and 82%, respectively, in the diagnosis, and
a sensitivity and specificity of 77% and 81% in the diagnosis of
vascular invasion. However, the results did indicate that the addi-
tion of other imaging modalities, such as EUS, could further
improve the diagnostic accuracy of vascular invasion.
Kim et al.,23 on the other hand, compared the accuracy of
MDCT in the pre-operative evaluation of resectability between
patients who had received neoadjuvant chemo-radiotherapy with
patients who had not received any neoadjuvant treatment. They
found no difference between the two groups (83% versus 81%). In
this previous study, the absence of para aortic lymph node
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metastasis (>1 cm in short axis) was considered a feature of resec-
tability in addition to the definition of resectability provided in
the methods section of this review.
Magnetic resonance imaging (MRI) and
magnetic resonance cholangio
pancreatography (MRCP)
In 1997, Trede et al.64 suggested that ultrafast MRI was the most
accurate staging modality when compared with percutaneous
ultrasonography, dual-phase helical CT, selective visceral angiog-
raphy and endoscopic retrograde cholangiopancreatography
(ERCP) for pancreatic and peri-ampullary tumours.
Megibow et al.36 found that MRI had a diagnostic accuracy of
70% for pancreatic carcinomas. Megibow et al. determined that
gradient-echo and T1-weighted spin-echo sequences ranked
equally in the evaluation of vascular invasion, T1-weighted spin-
echo sequences were preferred for assessing lymphadenopathy
and T2-weighted spin-echo sequences were preferred for detect-
ing hepatic metastases. Hanninen et al.34 noted that single-shot
thick slab MRCP had superior image quality as compared with
multi-section MRCP images. They also noted a significant
improvement in the diagnostic accuracy of MRCP by two readers
(89% and 84% vs. 72% and 69%) with the addition of T1 and
T2-weighted images. This led them to infer that a comprehensive
MR approach should comprise both MRCP techniques and
parenchymal sequences.34
More recently, Fusari et al.53 demonstrated sensitivity, specific-
ity, accuracy, positive and negative predictive values of 100%,
88%, 98%. 97% and 100%, respectively, for MRCP in terms of
diagnosis, and sensitivity, specificity, accuracy, positive and nega-
tive predictive values of 88%, 100%, 90%, 100% and 70%, respec-
tively, for the evaluation of resectability of pancreatic carcinomas.
Tapper et al.37 determined that MRCP had a 100% and 83%,
81% and 96%, and 87% and 95% sensitivity and accuracy rates in
the determination of resectability, arterial and venous involve-
ment in pancreatic head carcinomas. These results were similar to
those of Hochwald et al.35 who determined that MRI and MRCP
had a sensitivity of 100%, specificity of 83%, PPV of 94%, NPV of
100% and accuracy of 95% in determining resectability of pan-
creatic cancer. Resectability in this previous study was defined as
surgically removable with grossly negative margins. Hochwald
et al.35 noted that malignant lesions appeared as discrete,
hypointense masses with respect to background pancreatic paren-
chyma on post-contrast T1-weighted images. Based on a compari-
son of pre-operatively performed MDCT and MR imaging
with angiography with the intra-operative findings, Lee et al.,65
however, noted that both modalities demonstrated an equal
ability in detection, prediction of vascular involvement and deter-
mination of resectability for pancreatic ductal adenocarcinoma.
Miller et al.73 have provided specific scenarios in which MRCP
may add to the CT findings in the diagnosis and staging of tumours.
In case of patients suspected to have pancreatic tumours on CT
which would appear as hypoattenuating lesions on the arterial
phase but who have signs such as duct dilation or focal pancreatic
atrophy, MRCP may be useful in such ‘non-contour deforming’
lesions. The contrast resolution of MRI facilitates detection of such
small tumours on gadolinium-enhanced fat-suppressed images.
Similarly, in patients with a ‘double duct’ sign, Miller et al.73 sug-
gested that MRCP may be useful in differentiating a malignant
from a benign aetiology. They also suggested a complementary role
for MRCP in the characterization of suspected liver metastases and
the detection of omental and nodal lesions.
In patients with borderline resectable disease who received
down-staging chemotherapy, Donahue et al.74 studied the use of
CT and MRI signs pre-operatively. They noted that features sug-
gestive of vascular involvement persisted even after chemotherapy.
In spite of these features, patients underwent exploration with a
curative intent based on other characteristics such as a reduction
in tumour markers, a reduction in the size of the tumour on
imaging and good functional status. In 83% of patients in whom
a complete resection could be achieved, fibrosis, and not tumour,
was the cause for the observed ‘involvement’ noted on preopera-
tive imaging. Thus they concluded that CT and MRI had a low
sensitivity (71%) and specificity (58%) in predicting vascular
involvement and resectability in the post-chemotherapy setting.
Endoscopic ultrasonography (EUS)
Studies reporting the diagnostic ability of EUS in the past were
fraught with the bias that even benign lesions were included.
Hence care should be exerted when interpreting earlier results of
EUS.80
The three types of echoendoscopes available today include:
radial echoendoscopes that provide axial images that correspond
to the familiar computed tomography (CT) or magnetic reso-
nance imaging (MRI) slices, and provide images from 2700 or
3600, depending on the manufacturer; curvilinear echoendo-
scopes that provide an image parallel to the shaft of the endoscope
and allow for the visualization and directing of fine-needle aspi-
ration (FNA), fine-needle injection (FNI), stent placement and
other interventional EUS procedures; and finally the catheter-
based specialty probes that are high-frequency probes that are
passed through either a forward-viewing endoscope or a side-
viewing duodenoscope to provide direct visualization of a specific
area or lesion (i.e. submucosal mass, intraductal lesions or discrete
gastric lesion).50
EUS has emerged as a useful, albeit invasive, modality in the
diagnosis of pancreatic tumours with sensitivities and accuracy
approaching 100% and specificity >95% even for lesions
<2 cm.52,62,63,72 In ampullary tumours, EUS has been found to be
more sensitive and specific as compared with CT with a statisti-
cally significant (P < 0.05) strength of tumour and nodal
agreement with the final pathology in a cohort of 27 patients
(7.4% – T1; 48.1% – T2; 44.4% – T3 and 63% – N0 and 37% – N1
disease).71
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Tadic et al.51 published their experience of EUS-FNA for lesions
<3 cm in all portions of the pancreas and were able to demon-
strate a sensitivity, specificity, PPV, NPV and diagnostic accuracy
of 68%, 100%, 100%, 73% and 83%, respectively. Similarly, Fisher
et al.49 analysed their results of EUS-FNA for lesions <5 cm pre-
dominantly in the head of pancreas (73%) and found sensitivity,
specificity, PPV, NPV and accuracy of 94.3%, 100%, 100%, 72.2%
and 95%, respectively. The value of EUS as a medium to obtain
histological evidence is increasing and must be sought in centres
where the expertise for EUS is available.
While Cannon et al.54 found that the presence of an endobiliary
stent affected staging accuracy of EUS for ampullary lesions, Chen
et al.,55 in a recent study, found that stents did not affect the
staging accuracy.
Positron emission tomography (PET) scan
Pancreatic adenocarcinomas are 18F-Fluorodeoxyglucose (FDG)-
avid tumours and hence FDG PET is a useful investigation for the
detection of these lesions.
A recent meta-analysis69 on the role of PET-CT for the detec-
tion of pancreatic carcinoma demonstrated a pooled sensitivity of
90.1% for PET-CT as compared with EUS (81.2%) and a pooled
specificity of 80.1% as compared with 92.3% for EUS. These
results are similar to the findings of two previously published
reviews of literature42,47 on the role of PET-CT in pancreatic
cancer detection that had noted a sensitivity of 90% and 95% and
specificity from 82% and 100%, respectively.
While FDG PET may help differentiate pancreatic adenomas
from carcinomas by the lack of avidity to adenomas,70 the dif-
ferentiation from chronic active pancreatitis is difficult owing
to FDG uptake in the presence of inflammation.40 FDG uptake
has been noted in up to 13% of patients with chronic pancre-
atitis in the absence of acute inflammation48 but may increase
to as high as 100% in autoimmune chronic pancreatitis.46
However, the avid uptake of FDG in the salivary glands has been
suggested as useful clues associated with autoimmune pancreati-
tis that may help differentiate it from pancreatic cancer.45
Delayed image acquisition may help to differentiate chronic pan-
creatitis from pancreatic cancer.43 Similarly, in the future, the
development of tracers for PET measuring cellular proliferation
may help to reduce the false-positive uptake noted in chronic
pancreatitis.40
For staging of pancreatic cancer, PET-CT does not provide any
benefit in terms of local tumour and regional lymph nodal disease
spread.41,44 In terms of loco-regional staging, PET/CT has been
shown to be similar to CT (accuracy rate of 84–85%).67 For assess-
ing recurrent or progressive disease, PET-CT has been shown to be
more sensitive (90%) than CT (80%). The complimentary role of
PET-CT and CT was best demonstrated by Farma et al.68 who
demonstrated an improvement in the sensitivity by 30% by the
addition of PET-CT to CT in the initial staging of pancreatic
cancer.
Laparoscopic staging and laparoscopic
ultrasonography
The role of diagnostic laparoscopy and laparoscopic ultrasonog-
raphy in the diagnosis and staging of peri-ampullary and pancre-
atic cancer was aimed at detecting missed occult metastatic lesions
in the liver and peritoneal cavity.81 Thus the use of such a strategy
would seem most prudent in patients with locally advanced
cancers noted on imaging. For this indication, Shoup et al.39 were
able to demonstrate metastasis in up to 37% of these patients
causing them to be unresectable.
A recent meta-analysis38 addressed the role of staging laparos-
copy and laparoscopic ultrasonography for peri-ampullary and
pancreatic cancers. Twenty-two studies were included in the
analysis of which only six studies included patients with locally
advanced disease on CT scan. Staging laparoscopy and laparo-
scopic ultrasonography was found to have an overall sensitivity of
64% and specificity of 99% with an improvement in the resection
rate from 61% to 80%.
Comparative studies
Table 1 summarizes some of the studies comparing the efficacy of
CT, EUS and MRI/MRCP in the diagnosis, staging and determi-
nation of respectability of pancreatic and peri-ampullary
cancers.54–61
Legmann et al.63 compared the accuracy of CT vs. EUS in deter-
mining the T and N stage of the disease based on the size of the
lesion. The overall accuracy for T-staging was not different
between the two modalities (90% for EUS vs. 86% for CT). For T
stage lesions less than 15 mm, CT had a lower accuracy as com-
pared with EUS (66% vs. 90%). However, for lesions larger than
35 mm, CT had a better accuracy than EUS (100% vs. 86%). For
lymph nodal staging, EUS did perform marginally better than CT
(86% vs. 77%). These findings were similar to the findings of
Shoup et al.60 who also found EUS to have a higher accuracy
compared with CT for peri-ampullary tumours <2 cm in size
(90% vs. 70%).
Dewitt et al.62 compared CT and EUS in a prospective, obser-
vational cohort study in order to determine the accuracy of the
two modalities in staging tumours as well as determining resect-
ability. Surgically resected pancreatic cancer with negative micro-
scopic histological margins was considered resectable. Of the 80
patients with pancreatic cancer, EUS had a sensitivity of 98% as
compared with 86% for CT. EUS also had a significantly better
accuracy in terms of determining the T stage of the tumour. While
the two modalities were similar in terms of nodal staging, CT was
better able to identify patients amenable to a resection, although
the difference was not significant. Based on their findings they
concluded that although EUS was superior to CT in terms of
tumour detection and determination of T stage, the two modali-
ties were comparable in terms of nodal staging and determination
of resectability.
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Table 1 Studies comparing the efficacy of CT, EUS and MRI/MRCP in the evaluation of pancreatic and periampullary cancers54–61
Author Year Factor
analysed
Modality Sensitivity Specificity Accuracy Comments
Periampullary cancer
Howard TJ et al. 1997 Diagnosis and resectability Helical CT 63% 100% 85% EUS better for tumour detection but CT
better for determining tumour resectabilityEUS 75% 77% 76%
Rivadeneira et al. 2003 Diagnosis Helical CT 68% 50% 67% Linear array EUS consistently superior to
helical CT in preoperative local staging of
periampullary malignancies
Linear array EUS 100% 75% 98%
Nodal staging Helical CT 33% 92% 68%
Linear array EUS 61% 100% 84%
Vascular involvement Helical CT 45% 100% 88%
Linear array EUS 100% 100% 100%
Shoup et al. 2000 Diagnosis Axial / Helical CT 82% 66% CT – initial study of choice in patients with
suspected periampullary tumoursEUS 97% 33%
Nodal staging Axial / Helical CT 42% 73% EUS – superior for tumour detection and
predicting vascular invasionEUS 21% 80%
Vascular invasion Axial / Helical CT 80% 87%
EUS 20% 100%
Ampullary Tumours
Cannon et al. 1999 Tumour staging Helical CT – – 24% EUS – superior to CT and MRI in assessing
T stage but not N stage of ampullary
lesions
EUS – – 78%
MRI – – 46%
Nodal staging Helical CT – – 59%
EUS – – 68%
MRI – – 77%
Chen et al. 2009 Detection CT – – 28% EUS was superior to CT and was equivalent
to MRI for tumour detection and T and N
staging of ampullary tumours
EUS – – 98%
MRI – – 81%
Tumour staging CT – – 26%
EUS – – 73%
MRI – – 54%
Nodal staging CT – – 44%
EUS – – 67%
MRI – – 77%
Periampullary and Pancreatic Cancer
Midwinter et al. 1999 Venous involvement (SMV /
PV)
Spiral CT 56% 100% – EUS is an important additional investigation
to CTEUS 81% 86% –
Nodal staging Spiral CT 33% 86% –
EUS 44% 93% –
Arterial involvement (SMA) Spiral CT 50% 100% –
EUS 17% 67%
Pancreatic Cancer
Rosch et al. 1991 Diagnosis CT 77% 53% – EUS superior to CT in pancreatic tumour
diagnosisEUS 99% 100% –
Soriano et al. 2004 Locoregional extension Helical CT 66% 100% 74% Helical CT and EUS – most useful individual
imaging techniques in the staging of
pancreatic cancer
EUS 44% 100% 62%
MRI 53% 100% 68%
Nodal staging Helical CT 37% 795 62% In potentially resectable tumours –
sequential approach: initially helical CT
followed by confirmatory EUS – most
reliable and cost effective
EUS 36% 87% 65%
MRI 15% 93% 61%
Vascular invasion Helical CT 67% 94% 83%
EUS 42% 97% 76%
MRI 59% 84% 74%
Distant Metastases Helical CT 55% 96% 88%
EUS 0% 100% 855
MRI 30% 95% 83%
Abbreviations: PV, Portal Vein; SMA, Superior Mesenteric artery; SMV, Superior mesenteric vein.
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Park et al.66 found that gadolinium-enhanced dynamic three-
dimensional–gradient echo MRI with MRCP showed superior
tumour conspicuity and similar diagnostic performance com-
pared with MDCT in evaluating the resectability of pancreatic
cancer.
Discussion
While abdominal ultrasonography may be the first investigation
in patients with upper gastrointestinal and biliary complaints
(which could arise as a result of an underlying pancreatic malig-
nancy), CT and MRI/MRCP constitute the most commonly per-
formed primary investigations performed for the diagnosis and
staging of pancreatic and peri-ampullary cancers. The choice
between CT or MRI/MRCP is more often determined by the avail-
ability of the individual modality as well as the technical expertise
in reporting them at the individual centres.
The major advantage of CT in comparison with EUS is its
ability to provide an assessment of the entire abdominal cavity
thus providing more information than EUS on distant metastases.
In interpreting the results from the earlier studies, it should be
remembered that these studies were comparing EUS with older
generation CT scanners.
EUS appears to be most important in the assessment of lesions
not clearly detected, but suspected, on CT/MRI, as well as in
ampullary tumours.71 It thus serves as a useful complementary
investigation to CT82 or even MRI/MRCP.
The role of CT angiography in confirming vascular anatomy/
involvement has been recently reviewed by one of the authors6 and
has been strongly recommended in the pre-operative assessment
of patients deemed to be suitable for a pancreatoduodenectomy.
Specific indications where PET-CT may aid in the decision
making for tumours of the pancreas include: borderline resectable
disease, locally advanced disease and/or resectable disease with
suspected metastases.
Mayo et al.83 recently conducted a statewide review of all
patients with surgically managed pancreatic cancer from 1996 to
2003 using data from the Oregon State Cancer Registry and
found that the use of a CT scan formed the corner stone of
staging and determination of respectability. They also noted that
the use of laparoscopy, as a staging modality, was restricted to
those patients suspected to have metastatic disease not identifi-
able on imaging.
Although a cost-analysis in the United States indicated that the
routine use of laparoscopic staging did not add significantly to the
overall expense of treatment,84 the routine use of staging laparos-
copy in peripancreatic cancer was not found to be beneficial.85 The
role of staging laparoscopy and laparoscopic ultrasonography
definitely have a complimentary role to radiological imaging in
patients with locally advanced disease by helping to reduce the
number of non-therapeutic laparotomies.38
Figure 2 provides the authors’ algorithm to the pre-operative
evaluation of patients with pancreatic and peri-ampullary cancer.
It is pertinent to note that in spite of pre-operative imaging
suggesting the disease to be resectable, it is possible that the result-
ant exploration may not lead to a complete (R0) resection.
Borderline resectable tumours (defined above) constitute an
important class of such patients. While it has been shown that
such tumours which appear borderline resectable on pre-
operative imaging may be amenable to a complete resection,29 the
value of such resections in terms of overall survival need to be
better defined. Offering these patients neoadjuvant chemo-
radiotherapy has been suggested to be a viable option.21,30 In spite
of increasing surgical aggression and the availability of neoadju-
vant treatment algorithms, certain features noted on pre-
operative imaging have been linked to poor outcomes even in the
event of an apparently curative resection in non-metastatic pan-
creatic cancer. Some authors have used techniques such as corre-
lation of imaging with the surgical pathology86,87 to demonstrate
this aspect. These include:
1 Features of local unresectability, including peri-pancreatic infil-
tration and a tumour size >3 cm.88
2 Venous involvement – where the length of invasion is >3 cm.89
3 Arterial involvement on pre-operative imaging.90
With the increasing use of neoadjuvant chemo- and chemora-
diotherapy protocols in patients with borderline pancreatic
tumours, further studies are needed to determine the imaging
modalities that can best guide surgical decision making after
neoadjuvant therapy especially when offering these patients the
option of an exploration with the intent of cure.
Conclusion
MDCT with angiography usually constitutes the first imaging
modality in suspected cancers of the pancreas. MRI and MRCP
alternatively may be used in centres where these facilities are
readily available. The role of EUS appears complementary to the
conventional CT and MRI/MRCP. It is of most benefit in the
assessment of lesions not clearly detected on CT. PET-CT serves as
a useful complementary investigation in patients with locally
advanced disease to rule out metastases outside the abdomen.
Staging laparoscopy and laparoscopic ultrasonography may help
in the re-staging of locally advanced/borderline resectable lesions
treated with neo-adjuvant therapy.
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